2-piperidone has been researched along with glucagon-like peptide 1 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, JY; Choi, YJ; Hong, JH; Hwang, DM; Jang, IJ; Kim, JA; Kim, JR; Kim, KP; Kwon, OH; Lim, KS; Shin, HS; Shin, KH; Shin, SG; Yu, KS | 1 |
| Chung, CH; Jang, HC; Kim, JA; Kim, SW; Lee, WY; Min, KW; Nam-Goong, IS; Rhee, EJ; Shivane, VK; Sosale, AR | 1 |
| Ahn, JY; Cho, JY; Cho, YM; Jang, IJ; Kim, JA; Lee, H; Lee, S; Lim, KS; Shin, D; Yu, KS | 1 |
| Cheng, XW; Kim, DJ; Kim, SY; Kim, W; Kim, YG; Lee, A; Lee, KH; Lee, SH; Lim, SJ; Moon, JY; Seo, JW; Woo, JS | 1 |
| Hwang, DM; Jung, E; Kim, DW; Kim, J; Kim, SH; Kwon, OH; Lee, SM; Yim, HJ; Yoon, MK | 1 |
| Ahn, CH; Cho, YM; Kim, EK; Min, SH; Oh, TJ | 1 |
| Choi, SH; Lee, IK; Leem, J | 1 |
4 trial(s) available for 2-piperidone and glucagon-like peptide 1
| Article | Year |
|---|---|
Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Topics: Adolescent; Adult; Area Under Curve; Blood Glucose; Chromatography, High Pressure Liquid; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Food-Drug Interactions; Glucagon-Like Peptide 1; Half-Life; Humans; Insulin; Korea; Male; Metabolic Clearance Rate; Organic Chemicals; Piperidones; Pyrimidines; Young Adult | 2008 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Topics: Adolescent; Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrazines; Pyrimidines; Republic of Korea; Risk Reduction Behavior; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
Topics: Adult; Blood Glucose; Cross-Over Studies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Young Adult | 2014 |
Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.
Topics: Adiponectin; Adult; Aged; Apolipoprotein B-100; Apolipoprotein B-48; Blood Glucose; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Cytokines; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Endotoxemia; Endotoxins; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Resistance; Interleukin-6; Lipid Metabolism; Male; Middle Aged; Piperidones; Postprandial Period; Pyrimidines; RNA, Messenger; Subcutaneous Fat, Abdominal; Transcriptome; Triglycerides; Tumor Necrosis Factor-alpha | 2017 |
3 other study(ies) available for 2-piperidone and glucagon-like peptide 1
| Article | Year |
|---|---|
The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes.
Topics: Albuminuria; Animals; Apoptosis; Cardiomegaly; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Forkhead Box Protein O3; Forkhead Transcription Factors; Glucagon-Like Peptide 1; Glycated Hemoglobin; Immunohistochemistry; Kidney; Male; Mice; NADPH Oxidases; Piperidones; Podocytes; Proto-Oncogene Proteins c-akt; Pyrimidines; Ventricular Dysfunction | 2016 |
Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Kinetics; Male; Mice; Piperidones; Pyrimidines; Rats; Substrate Specificity | 2016 |
Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice.
Topics: Animals; Apoptosis; Chemokine CCL2; Cisplatin; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Heme Oxygenase-1; Inflammation Mediators; Kidney; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; NAD(P)H Dehydrogenase (Quinone); Piperidones; Protective Agents; Pyrimidines; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2017 |